Overview

A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Sm

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Treatments:

Cisplatin
Gemcitabine
Niacinamide
Sorafenib